vs
Side-by-side financial comparison of UP Fintech Holding Ltd (TIGR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
UP Fintech Holding Ltd is the larger business by last-quarter revenue ($107.6M vs $70.6M, roughly 1.5× Viridian Therapeutics, Inc.\DE). UP Fintech Holding Ltd runs the higher net margin — 28.4% vs -49.0%, a 77.5% gap on every dollar of revenue.
UP Fintech Holding Limited, operating under the Tiger Brokers brand, provides online financial services for global Chinese investors. It offers cross-market stock trading (US, Hong Kong, mainland China A-shares), fund management, margin financing and investor education for retail and institutional clients.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
TIGR vs VRDN — Head-to-Head
Income Statement — Q1 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $107.6M | $70.6M |
| Net Profit | $30.6M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | 28.4% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $70.6M | ||
| Q1 25 | $107.6M | — | ||
| Q2 24 | $166.4M | — |
| Q3 25 | — | $-34.6M | ||
| Q1 25 | $30.6M | — | ||
| Q2 24 | $15.2M | — |
| Q3 25 | — | -56.7% | ||
| Q1 25 | — | — | ||
| Q2 24 | 14.0% | — |
| Q3 25 | — | -49.0% | ||
| Q1 25 | 28.4% | — | ||
| Q2 24 | 9.1% | — |
| Q3 25 | — | — | ||
| Q1 25 | $0.01 | — | ||
| Q2 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $503.0M |
| Total Assets | — | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q1 25 | — | — | ||
| Q2 24 | $392.5M | — |
| Q3 25 | — | $503.0M | ||
| Q1 25 | — | — | ||
| Q2 24 | $501.2M | — |
| Q3 25 | — | $577.1M | ||
| Q1 25 | — | — | ||
| Q2 24 | $4.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-84.6M | ||
| Q1 25 | — | — | ||
| Q2 24 | $155.1M | — |
| Q3 25 | — | $-84.7M | ||
| Q1 25 | — | — | ||
| Q2 24 | $153.8M | — |
| Q3 25 | — | -120.1% | ||
| Q1 25 | — | — | ||
| Q2 24 | 92.4% | — |
| Q3 25 | — | 0.2% | ||
| Q1 25 | — | — | ||
| Q2 24 | 0.8% | — |
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | 10.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
